Payment overview · 2025
General Payments
$471.64
17 reported records · 9 companies
Healthcare provider profile · identity verified
Mohammad I Jamil, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PEORIA, AZ · NPI 1255419206
Verified facts
What the public records show
CMS Open Payments records show Mohammad I Jamil, MD received $471.64 in general payments during 2025 across 17 reported records.
INTUITIVE SURGICAL, INC. accounted for 38.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $183.01 | 38.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $102.42 | 21.7% | 7 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $49.27 | 10.4% | 2 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $28.93 | 6.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $26.81 | 5.7% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $23.75 | 5.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.14 | 4.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.51 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.80 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $288.63 | 15 |
| Travel and Lodging | $183.01 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $183.01 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $102.42 | 7 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $49.27 | 2 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $28.93 | 1 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $28.93 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $28.93 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $26.81 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 315 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 221 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 204 | 52 |
| Lisinopril | Lisinopril | 143 | 47 |
| Losartan Potassium | Losartan Potassium | 124 | 45 |
| Metformin Hcl | Metformin Hcl | 104 | 32 |
| Tramadol Hcl | Tramadol Hcl | 101 | 31 |
| Gabapentin | Gabapentin | 97 | 35 |
| Omeprazole | Omeprazole | 93 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 73 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 23 |
| Carvedilol | Carvedilol | 70 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 31 |
| Montelukast Sodium | Montelukast Sodium | 68 | 27 |
| Potassium Chloride | Potassium Chloride | 67 | 32 |
| Furosemide | Furosemide | 61 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 60 | 22 |
| Alendronate Sodium | Alendronate Sodium | 58 | 21 |
| Simvastatin | Simvastatin | 56 | 18 |
| Methocarbamol | Methocarbamol | 50 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 25 |
| Glimepiride | Glimepiride | 47 | 13 |
| Sertraline Hcl | Sertraline Hcl | 46 | 15 |
| Atenolol | Atenolol | 44 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 44 | 23 |
| Mirtazapine | Mirtazapine | 43 | 14 |
| Eliquis | Apixaban | 42 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 12 |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 30 |
| Temazepam | Temazepam | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Nifedipine Er | Nifedipine | 33 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Prednisone | Prednisone | 29 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | 23 |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Meloxicam | Meloxicam | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Drospirenone-Ethinyl Estradiol | Ethinyl Estradiol/Drospirenone | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Sumatriptan | Sumatriptan | 11 | suppressed |
| Trokendi Xr | Topiramate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $471.64 · 17 records | INTUITIVE SURGICAL, INC. | AIRSUPRA, ATRICLIP LAA EXCLUSION SYSTEM, CREON, Da Vinci Surgical System, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, INSPIRE, KRYSTEXXA, MOUNJARO, SAPIEN 3 Ultra RESILIA, SYNERGY ABLATION SYSTEM, TZIELD, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error